Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02890511
Other study ID # 107CS-2
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received August 29, 2016
Last updated February 9, 2017
Start date August 2010
Est. completion date October 2012

Study information

Verified date February 2017
Source Daehwa Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study of DHP107, a novel oral paclitaxel formulation, to determine maximum tolerated dose and recommended dose for phase II trial in patients with advanced solid cancer and explore efficacy of DHP107 in patients with gastric cancer


Description:

1. Primary objective To determine the maximum tolerated dose and the recommended dose for phase 2 clinical trial for the repeated administration of DHP107 (oral paclitaxel) on advanced solid cancer patients

2. Secondary objectives

- To identify the dose limiting toxicity and the safety (toxicity) of DHP107

- To evaluate the efficacy (tumor response rate) of DHP107

- To assess pharmacokinetic (PK) characteristics of DHP107


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Patients between 18 and 70 years old

2. Patients prognosed with advanced or metastatic solid cancer by histopathology or cytology analysis who have no available standard therapy or who have failed at least once with the standard therapy

3. Adequate bone marrow function, liver function and adequate kidney function

4. Eastern Cooperative Oncology Group performance status = 2

5. Life expectancy of 3 month or more

6. Written informed consent

Exclusion Criteria:

1. Major infectious or neurological disease and bowel obstruction

2. Brain metastasis or hematologic malignancy

3. Patients who underwent surgery, radiation therapy, hormone or chemotherapy within 4 weeks prior to the beginning of investigational drug administration

4. Patients with the history of failure to the taxane line of chemotherapy (with the exception of when it was used before 6 month as adjuvant therapy or when the treatment was discontinued due to docetaxel related side effect)

5. Patients who are required to continuously take P-gp (P-glycoprotein) suppressor, immune suppressor, proton-pump inhibitor or H2-receptor antagonist during clinical trial period

6. Patients deemed by the investigator to suffer from severe heart disease (myocardial infarction, congestive heart failure, arrythmia accompanying drastic changes on ECG, severe or unstable angina pectoris, or other severe heart disease) or accompanying other severe internal diseases (such as uncontrollable diabetes, chronic obstructive pulmonary disease)

7. Patients with prior history of participating in a clinical trial within 30 days from registration for current clinical trial

8. Patient with history of alcohol or drug abuse in the recent 3 months

9. Pregnant women, nursing mothers, or patients of childbearing age who did not agree to contraception (both men and women)

10. Patients with (or suspected to have) abnormality in bile acid secretion (e.g.,. patients with resected gallbladder)

11. Patients who had a history of serious gastrointestinal bleeding, or with diseases that could affect the absorption of oral medication (malabsorption syndrome, active peptic ulcer)

12. Patients with history of severe hypersensitive reaction to active ingredient and excipient of the investigational drug

13. Patient who are in a state that is deemed inappropriate to participate in the clinical trial by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Paclitaxel
Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.

Locations

Country Name City State
Korea, Republic of Asan Medical Center, University of Ulsan College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Daehwa Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with dose limiting toxicity(DLT) to determine maximum tolerated dose(MTD) To determine the dose at which no more than one patient out of up to 6 patients at the same dose level experience a drug-related dose-limiting toxicity First cycle of treatment (4-week)
Secondary To identify the dose limiting toxicity(DLT) and the safety (toxicity) of DHP107 Adverse events are evaluated in the first cycle(4-week) according to NCI CTCAE v4.0 First cycle of treatment (4-week)
Secondary To evaluate efficacy(tumor response) by RECIST criteria version 1.1 every 8 weeks (±1 week)
Secondary PK parameters for DHP107 derived from determining their plasma concentrations using validated assays. First cycle of treatment (4-week)
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2